hydroxychloroquine has been researched along with Heart Diseases in 17 studies
Hydroxychloroquine: A chemotherapeutic agent that acts against erythrocytic forms of malarial parasites. Hydroxychloroquine appears to concentrate in food vacuoles of affected protozoa. It inhibits plasmodial heme polymerase. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p970)
hydroxychloroquine : An aminoquinoline that is chloroquine in which one of the N-ethyl groups is hydroxylated at position 2. An antimalarial with properties similar to chloroquine that acts against erythrocytic forms of malarial parasites, it is mainly used as the sulfate salt for the treatment of lupus erythematosus, rheumatoid arthritis, and light-sensitive skin eruptions.
Heart Diseases: Pathological conditions involving the HEART including its structural and functional abnormalities.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Hydroxychloroquine and chloroquine are used extensively in malaria and rheumatological conditions, and now in COVID-19 prevention and treatment." | 3.96 | Concentration-dependent mortality of chloroquine in overdose. ( Baud, FJ; Clemessy, JL; Hoglund, RM; Megarbane, B; Tarning, J; Watson, JA; White, NJ, 2020) |
| "Aspirin has been shown to reduce the number of transient ischemic attacks (TIA), stroke and death in patients with multiple TIA." | 3.75 | Antithrombotic effects of drugs which suppress platelet function: their potential in prevention growth of tumour cells. ( Turpie, AG, 1982) |
| "Patients with systemic lupus erythematosus (SLE) have increased cardiovascular morbidity and mortality." | 2.77 | QT dispersion in patients with systemic lupus erythematosus: the impact of disease activity. ( Ghahartars, M; Kojuri, J; Liaghat, L; Mahmoody, Y; Nazarinia, MA; Rezaian, Gr, 2012) |
| "Hydroxychloroquine has been used for rheumatological diseases for many decades and is considered a safe medication." | 2.72 | Cardiac Complications Attributed to Hydroxychloroquine: A Systematic Review of the Literature Pre-COVID-19. ( Basir, MB; Fram, G; Kang, G; Khan, A; Malette, K; McKinnon, JE; O'Neill, WW; So, K; Villablanca, P; Wang, DD; Zervos, M, 2021) |
| "Hydroxychloroquine has been widely prescribed to treat patients with COVID-19 pneumonia." | 1.62 | Torsades de pointes in SARS-CoV-2 (COVID-19) pneumonia: medicine reconciliation and careful monitoring of QTc interval may help prevent cardiac complications. ( Ali, N; Aslam, W; Lamb, CR, 2021) |
| "This study indicates that Q fever exists in our population." | 1.51 | Ten-year experience of Q fever endocarditis in a tertiary cardiac center in Saudi Arabia. ( Akhtar, MY; Albalawi, R; Albarrag, AM; Alnajashi, K; Alsherbeeni, N; Alsufyani, E; Alzahrani, A; Elzein, FE; Kaabia, N; Mehdi, S; Raoult, D, 2019) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (11.76) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 4 (23.53) | 24.3611 |
| 2020's | 11 (64.71) | 2.80 |
| Authors | Studies |
|---|---|
| Vouri, SM | 1 |
| Thai, TN | 1 |
| Winterstein, AG | 1 |
| Nguyen, LS | 1 |
| Dolladille, C | 1 |
| Drici, MD | 1 |
| Fenioux, C | 1 |
| Alexandre, J | 1 |
| Mira, JP | 1 |
| Moslehi, JJ | 1 |
| Roden, DM | 1 |
| Funck-Brentano, C | 1 |
| Salem, JE | 1 |
| Kamp, TJ | 1 |
| Hamdan, MH | 1 |
| January, CT | 1 |
| Dos Reis Neto, ET | 1 |
| Kakehasi, AM | 1 |
| de Medeiros Pinheiro, M | 1 |
| Ferreira, GA | 1 |
| Marques, CDL | 1 |
| da Mota, LMH | 1 |
| Dos Santos Paiva, E | 1 |
| Pileggi, GCS | 1 |
| Sato, EI | 1 |
| Reis, APMG | 1 |
| Xavier, RM | 1 |
| Provenza, JR | 1 |
| Watson, JA | 1 |
| Tarning, J | 1 |
| Hoglund, RM | 1 |
| Baud, FJ | 1 |
| Megarbane, B | 1 |
| Clemessy, JL | 1 |
| White, NJ | 1 |
| Halm, MA | 1 |
| Patel, M | 1 |
| Gangemi, A | 1 |
| Marron, R | 1 |
| Chowdhury, J | 1 |
| Yousef, I | 1 |
| Zheng, M | 1 |
| Mills, N | 1 |
| Tragesser, L | 1 |
| Giurintano, J | 1 |
| Gupta, R | 1 |
| Gordon, M | 1 |
| Rali, P | 1 |
| D'Alonso, G | 1 |
| Fleece, D | 1 |
| Zhao, H | 1 |
| Patlakh, N | 1 |
| Criner, G | 1 |
| Fram, G | 1 |
| Wang, DD | 1 |
| Malette, K | 1 |
| Villablanca, P | 1 |
| Kang, G | 1 |
| So, K | 1 |
| Basir, MB | 1 |
| Khan, A | 1 |
| McKinnon, JE | 1 |
| Zervos, M | 1 |
| O'Neill, WW | 1 |
| Choi, SW | 1 |
| Shin, JS | 1 |
| Park, SJ | 1 |
| Jung, E | 1 |
| Park, YG | 1 |
| Lee, J | 1 |
| Kim, SJ | 1 |
| Park, HJ | 1 |
| Lee, JH | 1 |
| Park, SM | 1 |
| Moon, SH | 1 |
| Ban, K | 1 |
| Go, YY | 1 |
| Alkasir, A | 1 |
| Lippmann, S | 1 |
| Aslam, W | 1 |
| Lamb, CR | 1 |
| Ali, N | 1 |
| Chatre, C | 1 |
| Roubille, F | 1 |
| Vernhet, H | 1 |
| Jorgensen, C | 1 |
| Pers, YM | 1 |
| Elzein, FE | 1 |
| Alsherbeeni, N | 1 |
| Alnajashi, K | 1 |
| Alsufyani, E | 1 |
| Akhtar, MY | 1 |
| Albalawi, R | 1 |
| Albarrag, AM | 1 |
| Kaabia, N | 1 |
| Mehdi, S | 1 |
| Alzahrani, A | 1 |
| Raoult, D | 1 |
| Izmirly, PM | 1 |
| Kim, MY | 1 |
| Llanos, C | 1 |
| Le, PU | 1 |
| Guerra, MM | 1 |
| Askanase, AD | 1 |
| Salmon, JE | 1 |
| Buyon, JP | 1 |
| Kojuri, J | 1 |
| Nazarinia, MA | 1 |
| Ghahartars, M | 1 |
| Mahmoody, Y | 1 |
| Rezaian, Gr | 1 |
| Liaghat, L | 1 |
| SULLI, G | 1 |
| VARRONE, F | 1 |
| Turpie, AG | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Randomized Double-Blind Placebo-Controlled Trial on the Safety and Efficacy of Imatinib for Hospitalized Adults With COVID-19[NCT04394416] | Phase 3 | 204 participants (Anticipated) | Interventional | 2020-06-02 | Active, not recruiting | ||
| A Three-arm, Multicenter, Open-label Randomized Controlled Trial of Hydroxychloroquine and Low-dose Prednisone on Recurrent Spontaneous Abortion With Undifferentiated Connective Tissue Diseases: Protocol for the Immunosuppressant Regimens for Living FEtus[NCT03671174] | 420 participants (Anticipated) | Interventional | 2019-08-02 | Recruiting | |||
| QT Dispersion in Patients With Systemic Lupus Erythematosus: the Impact of Disease Activity[NCT01031797] | 124 participants (Actual) | Observational | 2008-01-31 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
7 reviews available for hydroxychloroquine and Heart Diseases
| Article | Year |
|---|---|
Chloroquine or Hydroxychloroquine for COVID-19: Is Cardiotoxicity a Concern?
Topics: Betacoronavirus; Cardiotoxicity; Chloroquine; Coronavirus Infections; COVID-19; Global Health; Heart | 2020 |
Revisiting hydroxychloroquine and chloroquine for patients with chronic immunity-mediated inflammatory rheumatic diseases.
Topics: Antimalarials; Antiphospholipid Syndrome; Antirheumatic Agents; Arthritis, Rheumatoid; Chloroquine; | 2020 |
COVID-19 and Antimalarial Drugs: Harms Outweigh Benefits.
Topics: Antimalarials; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; Heart Diseases; Hospi | 2020 |
Cardiac Complications Attributed to Hydroxychloroquine: A Systematic Review of the Literature Pre-COVID-19.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Cardiotoxins; COVID-19; Female; Heart Diseases; Humans; | 2021 |
Cardiac Complications Attributed to Chloroquine and Hydroxychloroquine: A Systematic Review of the Literature.
Topics: Antimalarials; Cardiotoxicity; Chloroquine; Dose-Response Relationship, Drug; Female; Heart Diseases | 2018 |
[EXTRAMALARIAL THERAPUETIC APPLICATIONS OF ANTIMALARIAL DRUGS. 1. CLINICAL UTILIZATIONS].
Topics: Amodiaquine; Antimalarials; Chloroquine; Collagen Diseases; Dermatology; Drug Utilization; Epilepsy; | 1963 |
Antithrombotic effects of drugs which suppress platelet function: their potential in prevention growth of tumour cells.
Topics: Aspirin; Blood Platelets; Cardiovascular Diseases; Cell Division; Clinical Trials as Topic; Coronary | 1982 |
2 trials available for hydroxychloroquine and Heart Diseases
| Article | Year |
|---|---|
QT dispersion in patients with systemic lupus erythematosus: the impact of disease activity.
Topics: Adrenal Cortex Hormones; Adult; Aged; Aged, 80 and over; Echocardiography; Electrocardiography; Fema | 2012 |
Antithrombotic effects of drugs which suppress platelet function: their potential in prevention growth of tumour cells.
Topics: Aspirin; Blood Platelets; Cardiovascular Diseases; Cell Division; Clinical Trials as Topic; Coronary | 1982 |
9 other studies available for hydroxychloroquine and Heart Diseases
| Article | Year |
|---|---|
An evaluation of co-use of chloroquine or hydroxychloroquine plus azithromycin on cardiac outcomes: A pharmacoepidemiological study to inform use during the COVID19 pandemic.
Topics: Adolescent; Adult; Aged; Azithromycin; Chloroquine; Cohort Studies; COVID-19; COVID-19 Drug Treatmen | 2021 |
Cardiovascular Toxicities Associated With Hydroxychloroquine and Azithromycin: An Analysis of the World Health Organization Pharmacovigilance Database.
Topics: Azithromycin; Cardiotoxicity; COVID-19; COVID-19 Drug Treatment; Databases, Factual; Electrocardiogr | 2020 |
Concentration-dependent mortality of chloroquine in overdose.
Topics: Adult; Antimalarials; Biotransformation; Chloroquine; Coronavirus Infections; COVID-19; COVID-19 Dru | 2020 |
Retrospective analysis of high flow nasal therapy in COVID-19-related moderate-to-severe hypoxaemic respiratory failure.
Topics: Adrenal Cortex Hormones; Aged; Anti-Bacterial Agents; Antibodies, Monoclonal, Humanized; Antirheumat | 2020 |
Antiviral activity and safety of remdesivir against SARS-CoV-2 infection in human pluripotent stem cell-derived cardiomyocytes.
Topics: Adenosine Monophosphate; Alanine; Amides; Animals; Antimalarials; Antiviral Agents; Chlorocebus aeth | 2020 |
COVID-19 and Cardiac Concerns for Psychiatric Patients.
Topics: Antidepressive Agents; Antiviral Agents; Arrhythmias, Cardiac; Atrial Fibrillation; Atrioventricular | 2020 |
Torsades de pointes in SARS-CoV-2 (COVID-19) pneumonia: medicine reconciliation and careful monitoring of QTc interval may help prevent cardiac complications.
Topics: Aged; Anti-Infective Agents; Citalopram; COVID-19 Drug Treatment; Dexamethasone; Donepezil; Drug The | 2021 |
Ten-year experience of Q fever endocarditis in a tertiary cardiac center in Saudi Arabia.
Topics: Adolescent; Adult; Anti-Bacterial Agents; Child; Doxycycline; Endocarditis, Bacterial; Female; Heart | 2019 |
Evaluation of the risk of anti-SSA/Ro-SSB/La antibody-associated cardiac manifestations of neonatal lupus in fetuses of mothers with systemic lupus erythematosus exposed to hydroxychloroquine.
Topics: Antirheumatic Agents; Autoantibodies; Autoantigens; Case-Control Studies; Female; Heart Diseases; Hu | 2010 |